Han Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Han Lin has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Bo Pang
Department of Brain Tumor Research Center, Beijing Neurosurgical Institute, Beijing Tiantan Hospital, Capital Medical University , Beijing
11 shared publications - Jiatong Gu
Capital Medical University 1 Beijing Institute of Brain Disorders Beijing, China
10 shared publications - Jun Yan
Capital Medical University 1 Beijing Institute of Brain Disorders Beijing, China
10 shared publications - Lulu Zhu
Capital Medical University 1 Beijing Institute of Brain Disorders Beijing, China
10 shared publications - Mingjuan Xun
Capital Medical University 1 Beijing Institute of Brain Disorders Beijing, China
10 shared publications - Shanshan Liu
National Clinical Research Center for Metabolic Diseases Key Laboratory of Diabetes Immunology, and Department of Metabolism and Endocrinology Ministry of Education The Second Xiangya Hospital of Central South University Changsha Hunan China
10 shared publications
Latest Publications
- 28 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
H3K27me3 loss and METTL3-m6A converge to upregulate SOX11/SMARCA4 and drive H3K27-altered spinal cord glioma stemness and proliferation
Background: H3 K27-altered diffuse midline gliomas (H3-DMGs) are driven by stem-like and proliferative tumor cells resulting from global H3K27me3 loss. Here, we aimed to identify key molecular mechanisms involved in the interplay between epigenetic and epitranscriptomic regulation underlying this process. Methods: Patient-derived spinal cord H3-DMG stem-like spheres and serum-induced differentiated cells were used to model tumor plasticity. Multi-omics approaches, including single-cell RNA sequencing, spatial transcriptomics, RNA m6A profiling, CUT&Tag, ATAC-seq, and in vitro and in vivo assays were performed to dissect epigenetic and epitranscriptomic regulation of stemness. Results: Differentiation reduced stemness markers, proliferation, H3K27M expression, and global m6A levels, while increasing H3K27me3. METTL3 was significantly downregulated during differentiation and positively correlated with stemness and proliferation in patient tumors. METTL3 promoted tumor stemness and growth by stabilizing SOX11 mRNA through YTHDC2-dependent m6A recognition. In parallel, H3K27me3 loss relieved transcriptional repression at both METTL3 and SOX11 loci, leading to SOX11 overexpression. Functionally, SOX11 interacted with SMARCA4, the core ATPase of the SWI/SNF complex, to enhance chromatin accessibility and activate stemness-associated transcriptional programs marked by H3K27ac and H3K4me3 enrichment. Clinically, METTL3 and SOX11 were upregulated in H3K27M-mutant tumors, and high SOX11 expression correlated with increased proliferation, poor prognosis, and enhanced sensitivity to the SMARCA4 inhibitor BRM014. Conclusions: H3K27M-driven epigenetic dysregulation promotes SOX11 overexpression through combined H3K27me3 loss and METTL3-mediated m6A modification. SOX11 sustains tumor stemness and proliferation by recruiting SMARCA4 to remodel chromatin and serves as both a prognostic biomarker and a predictor of response to SMARCA4-targeted therapy in spinal cord H3-DMG.
- 28 September 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
H3K27me3 loss and METTL3-m6A converge to upregulate SOX11/SMARCA4 and drive H3K27-altered spinal cord glioma stemness and proliferation
Background: H3 K27-altered diffuse midline gliomas (H3-DMGs) are driven by stem-like and proliferative tumor cells resulting from global H3K27me3 loss. Here, we aimed to identify key molecular mechanisms involved in the interplay between epigenetic and epitranscriptomic regulation underlying this process. Methods: Patient-derived spinal cord H3-DMG stem-like spheres and serum-induced differentiated cells were used to model tumor plasticity. Multi-omics approaches, including single-cell RNA sequencing, spatial transcriptomics, RNA m6A profiling, CUT&Tag, ATAC-seq, and in vitro and in vivo assays were performed to dissect epigenetic and epitranscriptomic regulation of stemness. Results: Differentiation reduced stemness markers, proliferation, H3K27M expression, and global m6A levels, while increasing H3K27me3. METTL3 was significantly downregulated during differentiation and positively correlated with stemness and proliferation in patient tumors. METTL3 promoted tumor stemness and growth by stabilizing SOX11 mRNA through YTHDC2-dependent m6A recognition. In parallel, H3K27me3 loss relieved transcriptional repression at both METTL3 and SOX11 loci, leading to SOX11 overexpression. Functionally, SOX11 interacted with SMARCA4, the core ATPase of the SWI/SNF complex, to enhance chromatin accessibility and activate stemness-associated transcriptional programs marked by H3K27ac and H3K4me3 enrichment. Clinically, METTL3 and SOX11 were upregulated in H3K27M-mutant tumors, and high SOX11 expression correlated with increased proliferation, poor prognosis, and enhanced sensitivity to the SMARCA4 inhibitor BRM014. Conclusions: H3K27M-driven epigenetic dysregulation promotes SOX11 overexpression through combined H3K27me3 loss and METTL3-mediated m6A modification. SOX11 sustains tumor stemness and proliferation by recruiting SMARCA4 to remodel chromatin and serves as both a prognostic biomarker and a predictor of response to SMARCA4-targeted therapy in spinal cord H3-DMG.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S1. Schematic of the Cre-LoxP-Mediated Gene Targeting to Generate gene-specific knockout mice.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S1. Schematic of the Cre-LoxP-Mediated Gene Targeting to Generate gene-specific knockout mice.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S2. Flow cytometry gating strategy.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S2. Flow cytometry gating strategy.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Table S1. Clinicopathological characteristics of the glioma patients (data obtained from Beijing Tian Tan Hospital, Capital Medical University).
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Table S1. Clinicopathological characteristics of the glioma patients (data obtained from Beijing Tian Tan Hospital, Capital Medical University).
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Data from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAM), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1–AMFR axis as a critical contributor to GBM progression through dual immunomodulatory and tumor-intrinsic mechanisms. Analysis of human glioma datasets and tissue samples revealed that CCL1—predominantly derived from TAMs—was significantly overexpressed in GBM and correlated with poor patient survival. Functionally, CCL1 recruited Arg1+ immunosuppressive macrophages in an AMFR-dependent manner. Myeloid-specific knockout of either Ccl1 or Amfr in murine models reduced TAM infiltration and extended survival. Although CCL1 can signal through both CCR8 and its recently identified receptor AMFR, AMFR played the dominant role in mediating CCL1-induced tumor cell proliferation and migration by activating the FAK and PI3K–AKT signaling pathways. Importantly, therapeutic neutralization of CCL1 using a monoclonal antibody significantly prolonged median survival in both immunocompetent GL261 murine GBM and BNI1-3 patient-derived xenograft models, accompanied by reduced TAM infiltration and attenuated FAK/PI3K–AKT signaling. Our findings establish TAM-derived CCL1 as a pivotal regulator of GBM pathogenesis and demonstrate that targeting the CCL1–AMFR axis disrupts both tumor-intrinsic growth and immunosuppressive TME dynamics, representing a promising therapeutic strategy for this lethal malignancy.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
The immunosuppressive tumor microenvironment (TME) in glioblastoma (GBM) is predominantly shaped by tumor-associated macrophages (TAM), yet the key chemokine axes driving immunosuppression and progression remain poorly defined. In this study, we identified the CCL1–AMFR axis as a critical contributor to GBM progression through dual immunomodulatory and tumor-intrinsic mechanisms. Analysis of human glioma datasets and tissue samples revealed that CCL1—predominantly derived from TAMs—was significantly overexpressed in GBM and correlated with poor patient survival. Functionally, CCL1 recruited Arg1+ immunosuppressive macrophages in an AMFR-dependent manner. Myeloid-specific knockout of either Ccl1 or Amfr in murine models reduced TAM infiltration and extended survival. Although CCL1 can signal through both CCR8 and its recently identified receptor AMFR, AMFR played the dominant role in mediating CCL1-induced tumor cell proliferation and migration by activating the FAK and PI3K–AKT signaling pathways. Importantly, therapeutic neutralization of CCL1 using a monoclonal antibody significantly prolonged median survival in both immunocompetent GL261 murine GBM and BNI1-3 patient-derived xenograft models, accompanied by reduced TAM infiltration and attenuated FAK/PI3K–AKT signaling. Our findings establish TAM-derived CCL1 as a pivotal regulator of GBM pathogenesis and demonstrate that targeting the CCL1–AMFR axis disrupts both tumor-intrinsic growth and immunosuppressive TME dynamics, representing a promising therapeutic strategy for this lethal malignancy.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S6. Analysis of protein expression and CCL1’s effect on the MAPK signaling pathway.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S6. Analysis of protein expression and CCL1’s effect on the MAPK signaling pathway.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S7. Validation of the CCL1 monoclonal antibody 3D9 by Western blot analysis.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S7. Validation of the CCL1 monoclonal antibody 3D9 by Western blot analysis.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S5. AMFR depletion in myeloid cells enhances cytotoxic T cells function.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S5. AMFR depletion in myeloid cells enhances cytotoxic T cells function.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S3. Association between CCL1 gene expression and prognosis in glioma patients.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S3. Association between CCL1 gene expression and prognosis in glioma patients.
- Open Access
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S4. Expression profiles of CCL1, CCR8 and AMFR in GBM.
- 2 April 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from CCL1–AMFR Facilitates Glioblastoma Progression by Modulating the Cross-talk between Glioma Cells and Tumor-Associated Macrophages
Figure S4. Expression profiles of CCL1, CCR8 and AMFR in GBM.